Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In

Executive Summary

The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion

You may also be interested in...



Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios

Vertex pays $60 million upfront to license two nucleotide polymerase inhibitors it will test in combination therapy with other HCV assets in its pipeline.

Active Deal-Making Year Anticipated In HCV As New, Better Drug Combos Emerge

Following the European Association for the Study of the Liver's annual meeting this past week in Vienna, Austria, it became clear that most companies active in the hepatitis C space hope to be part of the current best hope for HCV therapy: a once-daily, oral cocktail of antiviral drugs that will replace the current standard of care

Active Deal-Making Year Anticipated In HCV As New, Better Drug Combos Emerge

Following the European Association for the Study of the Liver's annual meeting this past week in Vienna, Austria, it became clear that most companies active in the hepatitis C space hope to be part of the current best hope for HCV therapy: a once-daily, oral cocktail of antiviral drugs that will replace the current standard of care

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel